Page 2 - Lobe Sciences News Today

Lobe Sciences Ltd. that Mathew Lee will join the organization as Chief Financial Officer, effective September 18, 2023. Mathew has over 15 years of experience as a finance executive. Mathew currently...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced that on August 30, 2023 it signed an amendment to...

Deep Dive - Lobe Sciences Ltd

Lobe Sciences Ltd. LOBEF, a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has…

Lobe Sciences Ltd. (OTCQB: LOBEF), a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical study on proprietary psilocin analog L-130. 

Phillips also named President of Altemia & Co., a Lobe Sciences Company ... | June 7, 2023

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has appointed Baxter Phillips III to the newly created position of chief operating officer (COO) effective...

17.05.2023 - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (Lobe or the Company), a biopharmaceutical company focused on developing transformative medicines to treat orphan diseases today announced it has entered into a commercial distribution agreement for ... Seite 1

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering

Orphan and rare diseases drug company Lobe Sciences Ltd. LOBEF is set to acquire Altemia & Company LLC. The deal includes all Altemnia assets, intellectual…